N/A
Completed N=20
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
Source: ClinicalTrials.gov NCT05002621 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcomePrimary: Differentially Expressed Genes — 149 differentially expressed gene
Summary
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Differentially Expressed Genes |
149 | — |
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years old.
- Diagnosis of SEA by a health care provider
- History of an absolute eosinophil count ≥ 300/mm^3
- Prescription for mepolizumab provided during course of routine clinical care but mepolizumab not yet started
Exclusion Criteria
- Age < 18 years old.
- Pregnancy.
- Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
- Currently using or any prior use of rituximab.
- History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
- Any prior history of malignancy, autoimmune disease, or immune deficiency.
- Any other significant medical issue as determined by the principal investigator.
Data sourced from ClinicalTrials.gov (NCT05002621). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.